Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of
mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary …

Purpose This review summarizes the development processes of hepatic impairment (HI)
PBPK models, examines current challenges, and proposes potential solutions. Recent …

Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …

Background Prescription information for many drugs entering the market lacks dosage
guidance for hepatic impairment. Dedicated studies for assessing the fate of drugs in hepatic …

Many narrow therapeutic index drugs are eliminated primarily by hepatic metabolism.
Selecting the proper dosing regimen for such drugs in the presence of liver disease is an …

After entry of a drug into the systemic circulation, duration and intensity of drug action is
determined to a large extent by the rate at which the drug is eliminated from the body. Drug …

The liver plays a central role in the pharmacokinetics of the majority of drugs. Liver
dysfunction may not only reduce the blood/plasma clearance of drugs eliminated by hepatic …

Chronic liver disease encompasses a large number of hepatic disorders. One of the most
important etiologies of liver disease is drug-induced liver disease, which is the leading …

Although the liver is the primary site of metabolism and biliary excretion for many
medications, data are limited on the liver's pharmacokinetic abilities in cirrhosis. Cirrhosis …

The article discusses the challenges and future considerations in evaluating
pharmacokinetics (PK) in liver disease, particularly hepatic dysfunction (HI), and the benefit …